Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: SAP30BP

Gene summary for SAP30BP

Gene summary.

Gene information	Species	Human
	Gene symbol	SAP30BP
	Gene ID	29115
	Gene name	SAP30 binding protein
	Gene Alias	HCNGP
	Cytomap	17q25.1
	Gene Type	protein-coding
	GO ID	GO:0006139
	UniProtAcc	Q9UHR5

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
29115	SAP30BP	LZE4T	Human	Esophagus	ESCC	5.47e-17	4.51e-01	0.0811
29115	SAP30BP	LZE5T	Human	Esophagus	ESCC	9.60e-03	3.21e-01	0.0514
29115	SAP30BP	LZE7T	Human	Esophagus	ESCC	7.81e-06	5.44e-01	0.0667
29115	SAP30BP	LZE8T	Human	Esophagus	ESCC	4.79e-07	2.50e-01	0.067
29115	SAP30BP	LZE20T	Human	Esophagus	ESCC	3.71e-08	8.82e-02	0.0662
29115	SAP30BP	LZE22T	Human	Esophagus	ESCC	4.18e-10	5.44e-01	0.068
29115	SAP30BP	LZE24T	Human	Esophagus	ESCC	1.80e-24	7.54e-01	0.0596
29115	SAP30BP	LZE21T	Human	Esophagus	ESCC	5.28e-07	5.32e-01	0.0655
29115	SAP30BP	LZE6T	Human	Esophagus	ESCC	1.16e-15	3.36e-01	0.0845
29115	SAP30BP	P1T-E	Human	Esophagus	ESCC	4.66e-10	4.76e-01	0.0875
29115	SAP30BP	P2T-E	Human	Esophagus	ESCC	5.88e-46	6.86e-01	0.1177
29115	SAP30BP	P4T-E	Human	Esophagus	ESCC	9.47e-15	3.04e-01	0.1323
29115	SAP30BP	P5T-E	Human	Esophagus	ESCC	1.44e-18	3.54e-01	0.1327
29115	SAP30BP	P8T-E	Human	Esophagus	ESCC	2.22e-42	6.19e-01	0.0889
29115	SAP30BP	P9T-E	Human	Esophagus	ESCC	1.54e-25	4.38e-01	0.1131
29115	SAP30BP	P10T-E	Human	Esophagus	ESCC	1.94e-47	8.63e-01	0.116
29115	SAP30BP	P11T-E	Human	Esophagus	ESCC	7.19e-33	1.01e+00	0.1426
29115	SAP30BP	P12T-E	Human	Esophagus	ESCC	3.93e-40	7.65e-01	0.1122
29115	SAP30BP	P15T-E	Human	Esophagus	ESCC	3.89e-34	6.97e-01	0.1149
29115	SAP30BP	P16T-E	Human	Esophagus	ESCC	5.11e-22	3.70e-01	0.1153

Page: 1 2 3 4 5 6 7

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:001657015	Esophagus	ESCC	histone modification	323/8552	463/18723	2.61e-26	7.88e-24	323
GO:000961518	Esophagus	ESCC	response to virus	238/8552	367/18723	6.65e-14	3.32e-12	238
GO:0044403111	Esophagus	ESCC	biological process involved in symbiotic interaction	186/8552	290/18723	1.43e-10	4.16e-09	186
GO:003105614	Esophagus	ESCC	regulation of histone modification	106/8552	152/18723	1.52e-09	3.55e-08	106
GO:00356015	Esophagus	ESCC	protein deacylation	79/8552	112/18723	8.30e-08	1.42e-06	79
GO:00987325	Esophagus	ESCC	macromolecule deacylation	80/8552	116/18723	3.19e-07	4.50e-06	80
GO:00165754	Esophagus	ESCC	histone deacetylation	60/8552	82/18723	3.85e-07	5.32e-06	60
GO:00310583	Esophagus	ESCC	positive regulation of histone modification	65/8552	92/18723	1.04e-06	1.31e-05	65
GO:00064765	Esophagus	ESCC	protein deacetylation	70/8552	101/18723	1.29e-06	1.58e-05	70
GO:005185115	Esophagus	ESCC	modulation by host of symbiont process	43/8552	60/18723	4.00e-05	3.22e-04	43
GO:005181714	Esophagus	ESCC	modulation of process of other organism involved in symbiotic interaction	54/8552	81/18723	1.09e-04	7.64e-04	54
GO:00903122	Esophagus	ESCC	positive regulation of protein deacetylation	20/8552	25/18723	4.81e-04	2.69e-03	20
GO:003582114	Esophagus	ESCC	modulation of process of other organism	64/8552	106/18723	1.61e-03	7.50e-03	64
GO:005170214	Esophagus	ESCC	biological process involved in interaction with symbiont	57/8552	94/18723	2.46e-03	1.07e-02	57
GO:00310652	Esophagus	ESCC	positive regulation of histone deacetylation	15/8552	19/18723	3.29e-03	1.35e-02	15
GO:00310631	Esophagus	ESCC	regulation of histone deacetylation	21/8552	31/18723	1.10e-02	3.70e-02	21
GO:00903114	Esophagus	ESCC	regulation of protein deacetylation	30/8552	48/18723	1.40e-02	4.57e-02	30
GO:004440312	Liver	Cirrhotic	biological process involved in symbiotic interaction	131/4634	290/18723	2.00e-14	1.84e-12	131
GO:00518171	Liver	Cirrhotic	modulation of process of other organism involved in symbiotic interaction	44/4634	81/18723	1.11e-08	4.26e-07	44
GO:005170211	Liver	Cirrhotic	biological process involved in interaction with symbiont	48/4634	94/18723	3.41e-08	1.14e-06	48

Page: 1 2 3 4 5 6 7

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

SAP30BP

SNV

Missense_Mutation

rs772155823

c.130G>A

p.Asp44Asn

p.D44N

Q9UHR5

protein_coding

tolerated_low_confidence(0.46)

benign(0.006)

TCGA-BH-A0DG-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

taxotere

SAP30BP

SNV

Missense_Mutation

novel

c.559G>C

p.Asp187His

p.D187H

Q9UHR5

protein_coding

deleterious(0)

probably_damaging(0.997)

TCGA-VS-A9U6-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

SAP30BP

SNV

Missense_Mutation

c.95G>A

p.Gly32Asp

p.G32D

Q9UHR5

protein_coding

tolerated_low_confidence(0.09)

benign(0)

TCGA-AA-3710-01

Colorectum

colon adenocarcinoma

Female

>=65

I/II

Unknown

SAP30BP

SNV

Missense_Mutation

novel

c.532G>A

p.Gly178Ser

p.G178S

Q9UHR5

protein_coding

deleterious(0)

probably_damaging(0.999)

TCGA-AA-3821-01

Colorectum

colon adenocarcinoma

Female

>=65

I/II

Unknown

SAP30BP

SNV

Missense_Mutation

novel

c.478N>T

p.Arg160Trp

p.R160W

Q9UHR5

protein_coding

deleterious(0.02)

probably_damaging(0.999)

TCGA-AA-A00N-01

Colorectum

colon adenocarcinoma

Male

>=65

I/II

Unknown

SAP30BP

SNV

Missense_Mutation

c.629N>C

p.Lys210Thr

p.K210T

Q9UHR5

protein_coding

deleterious(0)

probably_damaging(0.985)

TCGA-CM-6674-01

Colorectum

colon adenocarcinoma

Male

<65

I/II

Unknown

SAP30BP

SNV

Missense_Mutation

c.898N>T

p.Gly300Cys

p.G300C

Q9UHR5

protein_coding

deleterious(0)

probably_damaging(1)

TCGA-G4-6628-01

Colorectum

colon adenocarcinoma

Male

>=65

I/II

Unknown

SAP30BP

SNV

Missense_Mutation

novel

c.251N>A

p.Ala84Asp

p.A84D

Q9UHR5

protein_coding

tolerated_low_confidence(0.14)

benign(0)

TCGA-A5-A2K5-01

Endometrium

uterine corpus endometrioid carcinoma

Female

>=65

I/II

Unknown

SAP30BP

SNV

Missense_Mutation

novel

c.98N>A

p.Ser33Asn

p.S33N

Q9UHR5

protein_coding

tolerated_low_confidence(0.34)

benign(0.006)

TCGA-AP-A1DK-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

I/II

Unknown

SAP30BP

SNV

Missense_Mutation

novel

c.743N>T

p.Ala248Val

p.A248V

Q9UHR5

protein_coding

tolerated(0.27)

benign(0.006)

TCGA-AP-A1DK-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

I/II

Unknown

Page: 1 2 3

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1